Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8201a in HER2-positive metastatic breast cancer
NCT03248492Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Aug 2017; status: terminated.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03248492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248492.